auto_awesome
Want to know who else bid on this?
ProposalForge correlates this contract with the original RFP, the losing bidders, and the next recompete window.
Department
National Research Council CanadaAmount
$8.6M
Province
ABType
Contribution
Agreement Number
172-2021-2022-Q2-976618
Purpose
The Firm is Canada's leader in mRNA therapeutics and this project's main goal is to continue the development of PTX-COVID19-B by conducting a Phase II clinical trial with the goal of commercializing a made-in-Canada COVID-19 mRNA vaccine and the development and validation of mRNA vaccines targeting COVID-19 Variants of Concern.
Providence Therapeutics Holdings Inc. × National Research Council Canada
8 grants totalling $48.7M
Industrial Research Assistance Program – Contributions to Firms
26,784 grants totalling $5.1B
Related Grants
| Recipient | Amount | Program |
|---|---|---|
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| ILLUMIN INC. | $10.0M | Industrial Research Assistance Program –... |